http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 18 Aug 2026 16:11:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Solventum+Corp++++++++++++For%3A+Aug+17++Filed+by%3A+Zieselman+Neil+Craig/26944325.html si-local-file:///var/storage/secattach/20260818/26944325.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Solventum+Corp++++++++++++For%3A+Aug+17++Filed+by%3A+Zieselman+Neil+Craig/26944325.html Tue, 18 Aug 2026 16:11:00 -0400 O.03555807 SOLV SOLV.WI http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Solventum+Corp++++++++++++For%3A+Aug+17++Filed+by%3A+Zieselman+Neil+Craig/26944325.html si-local-file:///var/storage/secattach/20260818/26944325.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Solventum+Corp++++++++++++For%3A+Aug+17++Filed+by%3A+Zieselman+Neil+Craig/26944325.html Tue, 18 Aug 2026 16:11:00 -0400 O.03555807 SOLV SOLV.WI http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Solventum+Corp++++++++++++For%3A+Aug+17++Filed+by%3A+Zieselman+Neil+Craig/26944325.html si-local-file:///var/storage/secattach/20260818/26944325.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Solventum+Corp++++++++++++For%3A+Aug+17++Filed+by%3A+Zieselman+Neil+Craig/26944325.html Tue, 18 Aug 2026 16:11:00 -0400 O.03555807 SOLV SOLV.WI http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Solventum+Corp++++++++++++For%3A+Aug+10++Filed+by%3A+Zieselman+Neil+Craig/26944258.html si-local-file:///var/storage/secattach/20260818/26944258.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Solventum+Corp++++++++++++For%3A+Aug+10++Filed+by%3A+Zieselman+Neil+Craig/26944258.html Tue, 18 Aug 2026 16:08:00 -0400 O.03555807 SOLV SOLV.WI http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Solventum+Corp++++++++++++For%3A+Aug+10++Filed+by%3A+Zieselman+Neil+Craig/26944258.html si-local-file:///var/storage/secattach/20260818/26944258.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Solventum+Corp++++++++++++For%3A+Aug+10++Filed+by%3A+Zieselman+Neil+Craig/26944258.html Tue, 18 Aug 2026 16:08:00 -0400 O.03555807 SOLV SOLV.WI http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Solventum+Corp++++++++++++For%3A+Aug+10++Filed+by%3A+Zieselman+Neil+Craig/26944258.html si-local-file:///var/storage/secattach/20260818/26944258.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Solventum+Corp++++++++++++For%3A+Aug+10++Filed+by%3A+Zieselman+Neil+Craig/26944258.html Tue, 18 Aug 2026 16:08:00 -0400 O.03555807 SOLV SOLV.WI http://www.streetinsider.com/Press+Releases/The+GLP-1+Boom+Created+a+Tissue+Gap+Fillers+Were+Not+Built+For/26909984.html <p><strong>News Provided by USA News Group on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=jiZ7Nvpfe4ZxhDk2wSHeDmDH1wn8P8Qt6pacl4g8aiELZlUGKBxL9GYw6AqqjfwHAc7pylzBVwaW2qnpna82jjiEFFgdBFNhkxkrJSZPfhc=" rel="nofollow" target="_blank">USA News Group</a><strong> News Commentary - </strong>The weight-loss drug boom has been one of the defining healthcare stories of the decade, and <strong>its success has created a second-order opportunity that the drugs themselves were never designed to address</strong>. Rapid, large-volume weight loss does not only remove fat. It leaves behind slackened skin and hollowed facial and body contours that conventional dermal fillers and injectables, built for fine lines and modest volume, were never engineered to http://www.streetinsider.com/Press+Releases/The+GLP-1+Boom+Created+a+Tissue+Gap+Fillers+Were+Not+Built+For/26909984.html Wed, 12 Aug 2026 09:15:00 -0400 ABBV CNXU ESTA LLY SOLV http://www.streetinsider.com/Press+Releases/The+GLP-1+Boom+Created+a+Tissue+Gap+Fillers+Were+Not+Built+For/26909984.html <p><strong>News Provided by USA News Group on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=jiZ7Nvpfe4ZxhDk2wSHeDmDH1wn8P8Qt6pacl4g8aiELZlUGKBxL9GYw6AqqjfwHAc7pylzBVwaW2qnpna82jjiEFFgdBFNhkxkrJSZPfhc=" rel="nofollow" target="_blank">USA News Group</a><strong> News Commentary - </strong>The weight-loss drug boom has been one of the defining healthcare stories of the decade, and <strong>its success has created a second-order opportunity that the drugs themselves were never designed to address</strong>. Rapid, large-volume weight loss does not only remove fat. It leaves behind slackened skin and hollowed facial and body contours that conventional dermal fillers and injectables, built for fine lines and modest volume, were never engineered to http://www.streetinsider.com/Press+Releases/The+GLP-1+Boom+Created+a+Tissue+Gap+Fillers+Were+Not+Built+For/26909984.html Wed, 12 Aug 2026 09:15:00 -0400 ABBV CNXU ESTA LLY SOLV http://www.streetinsider.com/Press+Releases/The+GLP-1+Boom+Created+a+Tissue+Gap+Fillers+Were+Not+Built+For/26909984.html <p><strong>News Provided by USA News Group on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=jiZ7Nvpfe4ZxhDk2wSHeDmDH1wn8P8Qt6pacl4g8aiELZlUGKBxL9GYw6AqqjfwHAc7pylzBVwaW2qnpna82jjiEFFgdBFNhkxkrJSZPfhc=" rel="nofollow" target="_blank">USA News Group</a><strong> News Commentary - </strong>The weight-loss drug boom has been one of the defining healthcare stories of the decade, and <strong>its success has created a second-order opportunity that the drugs themselves were never designed to address</strong>. Rapid, large-volume weight loss does not only remove fat. It leaves behind slackened skin and hollowed facial and body contours that conventional dermal fillers and injectables, built for fine lines and modest volume, were never engineered to http://www.streetinsider.com/Press+Releases/The+GLP-1+Boom+Created+a+Tissue+Gap+Fillers+Were+Not+Built+For/26909984.html Wed, 12 Aug 2026 09:15:00 -0400 ABBV CNXU ESTA LLY SOLV http://www.streetinsider.com/Press+Releases/The+GLP-1+Boom+Created+a+Tissue+Gap+Fillers+Were+Not+Built+For/26909984.html <p><strong>News Provided by USA News Group on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=jiZ7Nvpfe4ZxhDk2wSHeDmDH1wn8P8Qt6pacl4g8aiELZlUGKBxL9GYw6AqqjfwHAc7pylzBVwaW2qnpna82jjiEFFgdBFNhkxkrJSZPfhc=" rel="nofollow" target="_blank">USA News Group</a><strong> News Commentary - </strong>The weight-loss drug boom has been one of the defining healthcare stories of the decade, and <strong>its success has created a second-order opportunity that the drugs themselves were never designed to address</strong>. Rapid, large-volume weight loss does not only remove fat. It leaves behind slackened skin and hollowed facial and body contours that conventional dermal fillers and injectables, built for fine lines and modest volume, were never engineered to http://www.streetinsider.com/Press+Releases/The+GLP-1+Boom+Created+a+Tissue+Gap+Fillers+Were+Not+Built+For/26909984.html Wed, 12 Aug 2026 09:15:00 -0400 ABBV CNXU ESTA LLY SOLV http://www.streetinsider.com/Press+Releases/The+GLP-1+Boom+Created+a+Tissue+Gap+Fillers+Were+Not+Built+For/26909984.html <p><strong>News Provided by USA News Group on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=jiZ7Nvpfe4ZxhDk2wSHeDmDH1wn8P8Qt6pacl4g8aiELZlUGKBxL9GYw6AqqjfwHAc7pylzBVwaW2qnpna82jjiEFFgdBFNhkxkrJSZPfhc=" rel="nofollow" target="_blank">USA News Group</a><strong> News Commentary - </strong>The weight-loss drug boom has been one of the defining healthcare stories of the decade, and <strong>its success has created a second-order opportunity that the drugs themselves were never designed to address</strong>. Rapid, large-volume weight loss does not only remove fat. It leaves behind slackened skin and hollowed facial and body contours that conventional dermal fillers and injectables, built for fine lines and modest volume, were never engineered to http://www.streetinsider.com/Press+Releases/The+GLP-1+Boom+Created+a+Tissue+Gap+Fillers+Were+Not+Built+For/26909984.html Wed, 12 Aug 2026 09:15:00 -0400 ABBV CNXU ESTA LLY SOLV http://www.streetinsider.com/Globe+Newswire/The+GLP-1+Boom+Created+a+Tissue+Gap+Fillers+Were+Not+Built+For/26909984.html <p><strong>News Provided by USA News Group on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=jiZ7Nvpfe4ZxhDk2wSHeDmDH1wn8P8Qt6pacl4g8aiELZlUGKBxL9GYw6AqqjfwHAc7pylzBVwaW2qnpna82jjiEFFgdBFNhkxkrJSZPfhc=" rel="nofollow" target="_blank">USA News Group</a><strong> News Commentary - </strong>The weight-loss drug boom has been one of the defining healthcare stories of the decade, and <strong>its success has created a second-order opportunity that the drugs themselves were never designed to address</strong>. Rapid, large-volume weight loss does not only remove fat. It leaves behind slackened skin and hollowed facial and body contours that conventional dermal fillers and injectables, built for fine lines and modest volume, were never engineered to http://www.streetinsider.com/Globe+Newswire/The+GLP-1+Boom+Created+a+Tissue+Gap+Fillers+Were+Not+Built+For/26909984.html Wed, 12 Aug 2026 09:15:00 -0400 ABBV CNXU ESTA LLY SOLV http://www.streetinsider.com/Globe+Newswire/The+GLP-1+Boom+Created+a+Tissue+Gap+Fillers+Were+Not+Built+For/26909984.html <p><strong>News Provided by USA News Group on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=jiZ7Nvpfe4ZxhDk2wSHeDmDH1wn8P8Qt6pacl4g8aiELZlUGKBxL9GYw6AqqjfwHAc7pylzBVwaW2qnpna82jjiEFFgdBFNhkxkrJSZPfhc=" rel="nofollow" target="_blank">USA News Group</a><strong> News Commentary - </strong>The weight-loss drug boom has been one of the defining healthcare stories of the decade, and <strong>its success has created a second-order opportunity that the drugs themselves were never designed to address</strong>. Rapid, large-volume weight loss does not only remove fat. It leaves behind slackened skin and hollowed facial and body contours that conventional dermal fillers and injectables, built for fine lines and modest volume, were never engineered to http://www.streetinsider.com/Globe+Newswire/The+GLP-1+Boom+Created+a+Tissue+Gap+Fillers+Were+Not+Built+For/26909984.html Wed, 12 Aug 2026 09:15:00 -0400 ABBV CNXU ESTA LLY SOLV http://www.streetinsider.com/Globe+Newswire/The+GLP-1+Boom+Created+a+Tissue+Gap+Fillers+Were+Not+Built+For/26909984.html <p><strong>News Provided by USA News Group on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=jiZ7Nvpfe4ZxhDk2wSHeDmDH1wn8P8Qt6pacl4g8aiELZlUGKBxL9GYw6AqqjfwHAc7pylzBVwaW2qnpna82jjiEFFgdBFNhkxkrJSZPfhc=" rel="nofollow" target="_blank">USA News Group</a><strong> News Commentary - </strong>The weight-loss drug boom has been one of the defining healthcare stories of the decade, and <strong>its success has created a second-order opportunity that the drugs themselves were never designed to address</strong>. Rapid, large-volume weight loss does not only remove fat. It leaves behind slackened skin and hollowed facial and body contours that conventional dermal fillers and injectables, built for fine lines and modest volume, were never engineered to http://www.streetinsider.com/Globe+Newswire/The+GLP-1+Boom+Created+a+Tissue+Gap+Fillers+Were+Not+Built+For/26909984.html Wed, 12 Aug 2026 09:15:00 -0400 ABBV CNXU ESTA LLY SOLV http://www.streetinsider.com/Globe+Newswire/The+GLP-1+Boom+Created+a+Tissue+Gap+Fillers+Were+Not+Built+For/26909984.html <p><strong>News Provided by USA News Group on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=jiZ7Nvpfe4ZxhDk2wSHeDmDH1wn8P8Qt6pacl4g8aiELZlUGKBxL9GYw6AqqjfwHAc7pylzBVwaW2qnpna82jjiEFFgdBFNhkxkrJSZPfhc=" rel="nofollow" target="_blank">USA News Group</a><strong> News Commentary - </strong>The weight-loss drug boom has been one of the defining healthcare stories of the decade, and <strong>its success has created a second-order opportunity that the drugs themselves were never designed to address</strong>. Rapid, large-volume weight loss does not only remove fat. It leaves behind slackened skin and hollowed facial and body contours that conventional dermal fillers and injectables, built for fine lines and modest volume, were never engineered to http://www.streetinsider.com/Globe+Newswire/The+GLP-1+Boom+Created+a+Tissue+Gap+Fillers+Were+Not+Built+For/26909984.html Wed, 12 Aug 2026 09:15:00 -0400 ABBV CNXU ESTA LLY SOLV http://www.streetinsider.com/Globe+Newswire/The+GLP-1+Boom+Created+a+Tissue+Gap+Fillers+Were+Not+Built+For/26909984.html <p><strong>News Provided by USA News Group on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=jiZ7Nvpfe4ZxhDk2wSHeDmDH1wn8P8Qt6pacl4g8aiELZlUGKBxL9GYw6AqqjfwHAc7pylzBVwaW2qnpna82jjiEFFgdBFNhkxkrJSZPfhc=" rel="nofollow" target="_blank">USA News Group</a><strong> News Commentary - </strong>The weight-loss drug boom has been one of the defining healthcare stories of the decade, and <strong>its success has created a second-order opportunity that the drugs themselves were never designed to address</strong>. Rapid, large-volume weight loss does not only remove fat. It leaves behind slackened skin and hollowed facial and body contours that conventional dermal fillers and injectables, built for fine lines and modest volume, were never engineered to http://www.streetinsider.com/Globe+Newswire/The+GLP-1+Boom+Created+a+Tissue+Gap+Fillers+Were+Not+Built+For/26909984.html Wed, 12 Aug 2026 09:15:00 -0400 ABBV CNXU ESTA LLY SOLV http://www.streetinsider.com/Analyst+PT+Change/Solventum+%28SOLV%29+PT+Raised+to+%24100+at+Stifel/26879453.html Stifel analyst Rick Wise raised the price target on Solventum (NYSE: SOLV) to $100.00 (from $90.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Solventum+%28SOLV%29+PT+Raised+to+%24100+at+Stifel/26879453.html Thu, 06 Aug 2026 08:10:18 -0400 SOLV http://www.streetinsider.com/Analyst+PT+Change/Solventum+%28SOLV%29+PT+Raised+to+%2484+at+BMO+Capital/26878995.html BMO Capital analyst Vik Chopra raised the price target on Solventum (NYSE: SOLV) to $84.00 (from $81.00) while maintaining a Market Perform rating. http://www.streetinsider.com/Analyst+PT+Change/Solventum+%28SOLV%29+PT+Raised+to+%2484+at+BMO+Capital/26878995.html Thu, 06 Aug 2026 07:50:46 -0400 SOLV http://www.streetinsider.com/Analyst+PT+Change/Solventum+%28SOLV%29+PT+Raised+to+%24105+at+Piper+Sandler/26878624.html Piper Sandler analyst Jason Bednar raised the price target on Solventum (NYSE: SOLV) to $105.00 (from $92.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Solventum+%28SOLV%29+PT+Raised+to+%24105+at+Piper+Sandler/26878624.html Thu, 06 Aug 2026 07:13:56 -0400 SOLV http://www.streetinsider.com/Analyst+PT+Change/Solventum+%28SOLV%29+PT+Raised+to+%24113+at+Mizuho/26878125.html Mizuho analyst Steven Valiquette raised the price target on Solventum (NYSE: SOLV) to $113.00 (from $100.00) while maintaining a Outperform rating. http://www.streetinsider.com/Analyst+PT+Change/Solventum+%28SOLV%29+PT+Raised+to+%24113+at+Mizuho/26878125.html Thu, 06 Aug 2026 06:52:44 -0400 SOLV http://www.streetinsider.com/Analyst+PT+Change/Solventum+%28SOLV%29+PT+Raised+to+%2489+at+Wells+Fargo/26877909.html Wells Fargo analyst Larry Biegelsen raised the price target on Solventum (NYSE: SOLV) to $89.00 (from $70.00) while maintaining a Equal Weight rating. http://www.streetinsider.com/Analyst+PT+Change/Solventum+%28SOLV%29+PT+Raised+to+%2489+at+Wells+Fargo/26877909.html Thu, 06 Aug 2026 06:38:58 -0400 SOLV http://www.streetinsider.com/Analyst+PT+Change/Solventum+%28SOLV%29+PT+Raised+to+%24102+at+KeyBanc/26877179.html KeyBanc analyst Brett Fishbin raised the price target on Solventum (NYSE: SOLV) to $102.00 (from $93.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Solventum+%28SOLV%29+PT+Raised+to+%24102+at+KeyBanc/26877179.html Thu, 06 Aug 2026 05:32:35 -0400 SOLV http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Solventum+Corp++++++++++++For%3A+Jun+30/26876104.html si-local-file:///var/storage/secattach/20260805/26876104.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Solventum+Corp++++++++++++For%3A+Jun+30/26876104.html Wed, 05 Aug 2026 17:28:00 -0400 O.03555807 SOLV http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Solventum+Corp++++++++++++For%3A+Jun+30/26876104.html si-local-file:///var/storage/secattach/20260805/26876104.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Solventum+Corp++++++++++++For%3A+Jun+30/26876104.html Wed, 05 Aug 2026 17:28:00 -0400 O.03555807 SOLV http://www.streetinsider.com/Earnings/Solventum+Corporation+%28SOLV%29+Tops+Q2+EPS+by+104c+%3B+Offers+Guidance/26875399.html <p>Solventum Corporation (NYSE: SOLV) reported Q2 EPS of $2.55, $1.04 better than the analyst estimate of $1.51. Revenue for the quarter came in at $2.2 billion.</p><p><strong>FY 2026 Outlook:-</strong></p><p>Increased adjusted EPS range to $7.10 to $7.20 vs consensus $6.55.</p><p>For earnings history and earnings-related data on Solventum Corporation (SOLV) <a href="http://www.streetinsider.com/ec_earnings.php?q=SOLV">click here</a>.</p> http://www.streetinsider.com/Earnings/Solventum+Corporation+%28SOLV%29+Tops+Q2+EPS+by+104c+%3B+Offers+Guidance/26875399.html Wed, 05 Aug 2026 16:47:32 -0400 SOLV